CANbridge Life Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CANbridge Life Sciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11300
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Canbridge Life Sciences Ltd (Canbridge) is a biopharmaceutical company that offers development and commercialization of specialty healthcare products. The company’s pipeline products include CAN-008, an antibody-like CD95 receptor and Fc-fusion protein used to reduce cancer-cell migration in malignant glioma and protecting tumor-infiltrating immune cells from apoptosis; CAN-002, calcium phosphate oral rinse solution indicated for mucositis caused by high dose chemotherapy and CAN-017, a humanized immunoglobulin gamma 1 and kappa monoclonal antibody, that targets the human v-erb-b2 oncogene homolog 3 (ERBB3 or HER-3) receptor. It has partnership with other bio-pharmaceutical companies and academic institutions. CANbridge is headquartered in Beijing, China.

CANbridge Life Sciences Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CANbridge Life Sciences Raises USD25 Million in Series B Financing 11
CANbridge Life Sciences Raises USD10 Million in Series A Venture Financing 12
Partnerships 13
CANbridge Pharma and WuXi Biologics Enter into Partnership 13
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 14
Licensing Agreements 15
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 15
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 16
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 18
Azaya Therapeutics Enters Into Licensing Agreement With Canbridge Life Sciences For ATI-1123 19
CANbridge Life Sciences Ltd – Key Competitors 21
CANbridge Life Sciences Ltd – Key Employees 22
CANbridge Life Sciences Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Jul 31, 2018: CANbridge Life Sciences Appoints Chief Medical Officer 24
Sep 12, 2017: CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CANbridge Life Sciences Raises USD25 Million in Series B Financing 11
CANbridge Life Sciences Raises USD10 Million in Series A Venture Financing 12
CANbridge Pharma and WuXi Biologics Enter into Partnership 13
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 14
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 15
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 16
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 18
Azaya Therapeutics Enters Into Licensing Agreement With Canbridge Life Sciences For ATI-1123 19
CANbridge Life Sciences Ltd, Key Competitors 21
CANbridge Life Sciences Ltd, Key Employees 22
CANbridge Life Sciences Ltd, Other Locations 23

List of Figures
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[CANbridge Life Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pharmagest Interactive SA (PHA):企業の財務・戦略的SWOT分析
    Summary Pharmagest Interactive SA (Pharmagest Interactive) is a technology company that develops and markets professional IT solutions for pharmacies and pharmaceutical industries. The company operates through four divisions such as pharmaceutical, fintech, e-health, and health and medico-social div …
  • Credit Saison Co., Ltd.:企業のM&A・事業提携・投資動向
    Credit Saison Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Credit Saison Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Nasser S. Al –Hajri Corp:企業の戦略的SWOT分析
    Nasser S. Al –Hajri Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • MORRE-TEC Industries, Inc.:戦略・SWOT・企業財務分析
    MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ambu AS (AMBU B):医療機器:M&Aディール及び事業提携情報
    Summary Ambu A/S (Ambu) is a medical device company that manufactures and markets life supporting devices. It focuses on single-use devices for anesthesia, patient monitoring and diagnostics, and emergency care. It serves hospitals, clinics, sleep laboratories and rescue services. The major products …
  • AVANGRID, Inc.:企業の戦略・SWOT・財務分析
    AVANGRID, Inc. - Strategy, SWOT and Corporate Finance Report Summary AVANGRID, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Theranyx Sarl:製薬・医療:M&Aディール及び事業提携情報
    Summary Theranyx Sarl is a bio technology company that develops novel therapeutic drugs and solutions to treat cancer. The company’s main line business involved in generation of functional antibodies to target GPCRs and ion channel receptors. Its antibodies named as Therabodies has scope in target v …
  • CytoSorbents Corp (CTSO):医療機器:M&Aディール及び事業提携情報
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …
  • Kolon Industries Inc (120110):企業の財務・戦略的SWOT分析
    Kolon Industries Inc (120110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • McPherson’s Ltd (MCP):企業の財務・戦略的SWOT分析
    McPherson's Ltd (MCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Jamaica Public Service Co Ltd:企業の戦略的SWOT分析
    Jamaica Public Service Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Alliance Data Systems Corp (ADS):企業の財務・戦略的SWOT分析
    Alliance Data Systems Corp (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Indoco Remedies Ltd (INDOCO):製薬・医療:M&Aディール及び事業提携情報
    Summary Indoco Remedies Ltd (Indoco Remedies) is a research-oriented pharmaceutical company that manufactures and markets formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). It has products portfolio in various therapeutic segments such as cardiovascular, central nervo …
  • Aviragen Therapeutics Inc (AVIR)-製薬・医療分野:企業M&A・提携分析
    Summary Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, ora …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formu …
  • GREENoneTEc Solarindustrie GmbH:企業の戦略的SWOT分析
    GREENoneTEc Solarindustrie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Nine Dragons Paper (Holdings) Limited:戦略・SWOT・企業財務分析
    Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Transmetro Corporation Limited
    Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Empyrean Energy PLC (EME):企業の財務・戦略的SWOT分析
    Summary Empyrean Energy PLC (Empyrean) is an oil and gas company. It carries out acquisition, exploration, development and production of crude oil and natural gas. The company operates offshore oil production reserves in China and Indonesia. Empyrean's production assets include Block 29/11, Pearl Ri …
  • Calgary Scientific Inc:医療機器:M&Aディール及び事業提携情報
    Summary Calgary Scientific Inc (Calgary Scientific) is a medical imaging company that provides research and diagnostic technologies for the medical industry. The company offers ResolutionMD, is a zero-footprint enterprise viewing platform, which is installed in healthcare facilities and used to view …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆